This site is intended for healthcare professionals

Aumolertinib significantly prolongs progression-free survival (PFS) with fewer side effects in first-line treatment of advanced EGFR-mutated NSCLC.- EQRx + Hansoh Pharma

Read time: 1 mins
Last updated:28th Jun 2021
Published:23rd May 2021
Detailed results from the Phase III AENEAS trial showed that treatment with aumolertinib from EQRx + Hansoh Pharma, resulted in a clinically significant improvement in progression-free survival (PFS) as compared to gefitinib (Iressa) in first-line treatment in patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) in patients with the most common types of EGFR mutations. In addition, the encouraging safety findings of less frequent rash and diarrhea confirmed the previously reported findings in the second-line APOLLO study.
Condition: NSCLC / EGFR
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest